New developments in the management of chemotherapy-induced emesis: do they impact on existing guidelines?
Guidelines for the management of chemotherapy-induced emesis are necessary to help clinicians match the emetogenicity of antineoplastic agents with the abundance of antiemetic agents now available. Numerous guidelines for antiemetic therapy currently exist, but compliance with them is inconsistent, in part because optimal antiemetic protection is not yet possible, even with the best guidelines. For this reason, guidelines must be dynamic and evolve as knowledge increases. Revision of antiemetic guidelines should be prompted by changes in general principles of treatment, not changes in specific details. Recent recognition of the unique benefits of incorporating selective neurokinin-1 receptor antagonists into regimens for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy, particularly in delayed emesis, justifies modification of existing antiemetic guidelines.
Grunberg
Steven M
SM
Department of Medicine, University of Vermont, Burlington, Vermont, USA.
D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D006287:Health Planning Guidelines; D006801:Humans; D064729:Neurokinin-1 Receptor Antagonists; D017410:Practice Guidelines as Topic; D014839:Vomiting / Q000139:chemically induced*
D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists